Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
10.22
Nov 03 • 3:59 PM ET Dollar change+0.04 Percentage change(0.39%)
Aftermarket Close
10.22
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
527.55M
Enterprise Value
438.47M
Income
26.72M
Sales
231.24M
Book/sh
2.71
Cash/sh
1.82
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
179
IPO
Apr 20, 2012
P/E
19.79
Forward P/E
-
PEG
-
P/S
2.28
P/B
3.77
P/C
5.62
P/FCF
12.82
EV/EBITDA
10.74
EV/Sales
1.90
Quick Ratio
2.64
Current Ratio
2.91
Debt/Eq
0.03
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
0.52
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
0.05% 0.29%
EPS Y/Y TTM
-46.26%
Sales Y/Y TTM
-2.86%
EPS Q/Q
33.30%
Sales Q/Q
7.75%
Insider Own
22.35%
Insider Trans
-1.78%
Inst Own
67.66%
Inst Trans
2.45%
ROA
13.78%
ROE
21.97%
ROIC
18.70%
Gross Margin
74.83%
Oper. Margin
13.16%
Profit Margin
11.55%
SMA20
-2.18%
SMA50
3.69%
SMA200
28.52%
Trades
Shs Outstand
51.10M
Shs Float
40.08M
52W High
11.50 -11.13%
52W Low
4.57 123.39%
Volatility
3.43% 4.36%
ATR (14)
0.42
RSI (14)
49.18
Beta
1.34
Rel Volume
1.22
Avg Volume
334.20K
Volume
406,521
Perf Week
-6.41%
Perf Month
5.69%
Perf Quarter
27.91%
Perf Half Y
39.05%
Perf YTD
71.76%
Perf Year
102.78%
Perf 3Y
267.63%
Perf 5Y
55.32%
Perf 10Y
-70.46%
Prev Close
10.18
Price
10.22
Change %
0.39%
Consensus
Hold
Avg. Price Target
$6.00
Implied Upside
-41.3%
Analysts10incl. previous ratings
Rating Distribution3 Buy · 4 Hold · 3 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 28, 2021Upgrade
C logoCCitigroup
Neutral → Buy$11+7.6%
Jun 25, 2020Resumed
BAC logoBBofA/Merrill
Underperform$9-11.9%
Oct 08, 2019Downgrade
GS logoGGoldman
Neutral → Sell$24 → $8-21.7%
May 10, 2019Downgrade
C logoCCitigroup
Buy → Neutral$24+134.8%
May 10, 2019Downgrade
CCantor Fitzgerald
Overweight → Neutral$57 → $20+95.7%
Jan 17, 2019Initiated
LLeerink Partners
Mkt Perform$21+105.5%
Jan 03, 2019Downgrade
GGuggenheim
Buy → Neutral
Nov 19, 2018Upgrade
GS logoGGoldman
Sell → Neutral
Nov 02, 2018Downgrade
JPM logoJJP Morgan
Neutral → Underweight
Nov 02, 2018Downgrade
BAC logoBBofA/Merrill
Buy → Underperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILSON TROY EDWARDDirectorSep 14 '26Sale9.105,00045,50054,750Sep 16 09:13 PM
Cesano AlessandraDirectorSep 14 '26Option Exercise2.9350,000146,500118,850Sep 16 09:06 PM
Cesano AlessandraDirectorSep 14 '26Sale9.1262,150566,99456,700Sep 16 09:06 PM
Cesano AlessandraDirectorSep 14 '26Proposed Sale9.1062,150565,565Sep 14 12:05 PM
WILSON TROY EDWARDDirectorSep 14 '26Proposed Sale9.105,00045,500Sep 14 12:01 PM
AUERBACH ALAN HPresident and CEOJul 06 '26Sale8.2644,058364,0517,261,671Jul 08 08:21 PM
HUNT DOUGLAS MSee RemarksJul 06 '26Sale8.268,46069,905196,841Jul 08 08:19 PM
NOUGUES MAXIMO FChief Financial OfficerJul 06 '26Sale8.269,38677,557230,637Jul 08 08:18 PM
AUERBACH ALAN HOfficerJul 06 '26Proposed Sale8.2644,058364,042Jul 06 04:56 PM
HUNT DOUGLAS MOfficerJul 06 '26Proposed Sale8.268,46069,903Jul 06 04:49 PM
NOUGUES MAXIMO FOfficerJul 06 '26Proposed Sale8.269,38677,555Jul 06 04:44 PM
WILSON TROY EDWARDDirectorJun 12 '26Sale7.2010,80077,74859,750Jun 15 08:16 PM
Stuglik Brian MDirectorJun 12 '26Sale7.208,10058,311113,858Jun 15 08:14 PM
Senderowicz AdrianDirectorJun 12 '26Sale7.2027,000194,31127,000Jun 15 08:13 PM
MOYES JAY MDirectorJun 12 '26Sale7.2222,000158,79658,322Jun 15 08:10 PM
Dorval AllisonDirectorJun 12 '26Sale7.2011,61083,57990,780Jun 15 08:09 PM
Senderowicz AdrianDirectorJun 12 '26Proposed Sale7.2627,000196,020Jun 12 10:39 AM
MOYES JAY MDirectorJun 12 '26Proposed Sale7.2622,000159,720Jun 12 10:37 AM
Dorval AllisonDirectorJun 12 '26Proposed Sale7.2611,61084,289Jun 12 10:33 AM
Stuglik Brian MDirectorJun 12 '26Proposed Sale7.268,10058,806Jun 12 10:23 AM
WILSON TROY EDWARDDirectorJun 12 '26Proposed Sale7.2610,80078,408Jun 12 09:58 AM
AUERBACH ALAN HPresident and CEOJan 07 '26Sale5.8818,012105,8937,145,951Jan 08 08:27 PM
AUERBACH ALAN HPresident and CEOJan 06 '26Sale5.8416,93898,9867,163,963Jan 08 08:27 PM
HUNT DOUGLAS MSee RemarksJan 07 '26Sale5.885,01429,477155,907Jan 08 08:15 PM
HUNT DOUGLAS MSee RemarksJan 06 '26Sale5.843,97323,218160,921Jan 08 08:15 PM
NOUGUES MAXIMO FChief Financial OfficerJan 07 '26Sale5.886,40537,655193,284Jan 08 08:14 PM
NOUGUES MAXIMO FChief Financial OfficerJan 06 '26Sale5.844,54026,532199,689Jan 08 08:14 PM
AUERBACH ALAN HOfficerJan 07 '26Proposed Sale5.8818,012105,893Jan 07 04:28 PM
HUNT DOUGLAS MOfficerJan 07 '26Proposed Sale5.885,01429,477Jan 07 04:25 PM
NOUGUES MAXIMO FOfficerJan 07 '26Proposed Sale5.886,40537,655Jan 07 04:24 PM
NOUGUES MAXIMO FOfficerJan 06 '26Proposed Sale5.844,54026,530Jan 06 04:53 PM
HUNT DOUGLAS MOfficerJan 06 '26Proposed Sale5.843,97323,217Jan 06 04:45 PM
AUERBACH ALAN HOfficerJan 06 '26Proposed Sale5.8416,93898,979Jan 06 04:44 PM
MILLER MICHAEL PATRICKDirectorNov 11 '25Sale4.8620,00097,22854,000Nov 13 04:41 PM
MILLER MICHAEL PATRICKDirectorNov 11 '25Proposed Sale4.8620,00097,228Nov 12 08:29 AM
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
FounderMr. Alan H. Auerbach
CFO & Principal Accounting OfficerMr. Maximo F. Nougues
FRAPSMr. Douglas Hunt B.Sc.
Chief Accounting OfficerMr. Gordon G. Esplin
Senior Director of Investor RelationsMr. Mariann Ohanesian